Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLD NYSE:MBX NASDAQ:MRUS NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$7.85-0.4%$6.61$5.51▼$12.65$2.42B0.553.87 million shs5.26 million shsMBXMBX Biosciences$14.40-1.2%$13.13$4.81▼$27.50$483.75MN/A324,482 shs215,057 shsMRUSMerus$66.62+0.5%$61.76$33.19▼$69.20$5.04B1.19857,798 shs589,537 shsXENEXenon Pharmaceuticals$38.83-1.2%$34.11$26.74▼$46.00$2.99B1.17883,660 shs750,219 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics+3.82%+4.79%+24.68%+29.18%-32.13%MBXMBX Biosciences-3.45%-5.20%+5.96%+6.82%+1,456,999,900.00%MRUSMerus+0.70%-0.84%+1.13%+15.14%+30.03%XENEXenon Pharmaceuticals+1.52%+1.68%+28.85%+29.02%-2.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFOLDAmicus Therapeutics4.1075 of 5 stars3.42.00.04.32.30.01.9MBXMBX Biosciences2.3171 of 5 stars3.50.00.00.02.21.70.6MRUSMerus2.985 of 5 stars3.53.00.00.03.52.50.0XENEXenon Pharmaceuticals2.6688 of 5 stars3.52.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.80Moderate Buy$16.22106.65% UpsideMBXMBX Biosciences 3.00Buy$37.63161.28% UpsideMRUSMerus 3.08Buy$88.7533.22% UpsideXENEXenon Pharmaceuticals 3.00Buy$53.3037.27% UpsideCurrent Analyst Ratings BreakdownLatest MBX, XENE, MRUS, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$55.008/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$90.008/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$97.00 ➝ $96.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$528.29M4.58N/AN/A$0.66 per share11.89MBXMBX BiosciencesN/AN/AN/AN/AN/AN/AMRUSMerus$56.23M89.61N/AN/A$11.13 per share5.99XENEXenon Pharmaceuticals$7.50M399.20N/AN/A$8.22 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$56.11M-$0.12N/A18.26N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/AMRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest MBX, XENE, MRUS, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics1.923.212.29MBXMBX BiosciencesN/AN/AN/AMRUSMerusN/A8.398.39XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AMBXMBX BiosciencesN/AMRUSMerus96.14%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%MBXMBX Biosciences52.19%MRUSMerus3.70%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/AMRUSMerus3775.63 million72.84 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableMBX, XENE, MRUS, and FOLD HeadlinesRecent News About These CompaniesXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3 at 10:38 AM | msn.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Braidwell LPSeptember 3 at 7:41 AM | marketbeat.comAnalysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $53.20September 1 at 2:31 AM | americanbankingnews.comDriehaus Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 31 at 7:14 AM | marketbeat.comSiren L.L.C. Sells 11,008 Shares of Xenon Pharmaceuticals Inc. $XENEAugust 31 at 6:29 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesAugust 31 at 2:27 AM | marketbeat.comXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 30, 2025 | finanznachrichten.deXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 29, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 29, 2025 | globenewswire.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 27, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by T. Rowe Price Investment Management Inc.August 26, 2025 | marketbeat.comEntryPoint Capital LLC Makes New $298,000 Investment in Xenon Pharmaceuticals Inc. $XENEAugust 25, 2025 | marketbeat.comDid Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?August 24, 2025 | finance.yahoo.comWellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENEAugust 24, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLCAugust 23, 2025 | marketbeat.comCandriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENEAugust 23, 2025 | marketbeat.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)August 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLCAugust 22, 2025 | marketbeat.comAn Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% UndervaluedAugust 21, 2025 | finance.yahoo.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plcAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBX, XENE, MRUS, and FOLD Company DescriptionsAmicus Therapeutics NASDAQ:FOLD$7.85 -0.03 (-0.38%) Closing price 04:00 PM EasternExtended Trading$7.86 +0.02 (+0.19%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.MBX Biosciences NYSE:MBX$14.40 -0.17 (-1.17%) Closing price 04:00 PM EasternExtended Trading$14.40 -0.01 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Merus NASDAQ:MRUS$66.62 +0.32 (+0.48%) Closing price 04:00 PM EasternExtended Trading$64.98 -1.64 (-2.46%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Xenon Pharmaceuticals NASDAQ:XENE$38.83 -0.47 (-1.20%) Closing price 04:00 PM EasternExtended Trading$38.00 -0.83 (-2.13%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
